- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Ribosomal Protein.
Displaying page 1 of 1.
EudraCT Number: 2016-002399-28 | Sponsor Protocol Number: RAP-ALS | Start Date*: 2017-07-14 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA | |||||||||||||
Full Title: Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis | |||||||||||||
Medical condition: definite or probable ALS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001785-29 | Sponsor Protocol Number: ARIS2 | Start Date*: 2016-08-15 |
Sponsor Name:St. Vincent's University Hospital | ||
Full Title: Combined Effect of CFTR Modifiers and Intensive Antibiotic Treatment | ||
Medical condition: Cystic fibrosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001468-39 | Sponsor Protocol Number: GS-US-313-1090 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
Full Title: Phase 1b trial evaluating idelalisib in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma or mediastinal B-cell lymphoma in combination with RICE | ||||||||||||||||||
Medical condition: B-cell malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001269-18 | Sponsor Protocol Number: D-IVa/D-IVb | Start Date*: 2013-12-19 |
Sponsor Name:Universitätsklinikum Ulm (AöR) | ||
Full Title: A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). | ||
Medical condition: Everolimus/ribociclib cohort (D-IVa): Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and ind... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004568-72 | Sponsor Protocol Number: ASTX029-01 | Start Date*: 2021-05-27 | ||||||||||||||||||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: Advanced Solid Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.